Alkermes plc.

ALKSSEC EDGAR

Pharmaceutical PreparationsCIK: 1520262

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$1.7B	$1.1B	$1.2B	$1.0B	$1.2B
Cost of Goods and Services Sold	$253.0M	$218.1M	$197.3M	$178.3M	$180.4M
Research and Development Expense	$270.8M	$272.7M	$290.9M	$394.6M	$512.8M
Selling, General and Administrative Expense	$689.8M	$590.8M	$549.6M	$538.8M	$599.4M
Operating Income (Loss)	$414.1M	-$6.1M	$97.7M	-$112.4M	-$175.5M
Interest Expense	—	—	$11.2M	$8.7M	$13.6M
Nonoperating Income (Expense)	$7.4M	-$25.0M	-$10.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$2.1B	$2.1B	$2.0B	$2.0B	$1.9B
Assets, Current	$1.4B	$1.5B	$1.1B	$1.1B	$1.1B
Cash and Cash Equivalents, at Carrying Value	$457.5M	$457.5M	$292.5M	$337.5M	$273.0M
Inventory, Net	$182.9M	$186.4M	$181.4M	$150.3M	$125.7M
Liabilities	$590.6M	$933.5M	$920.2M	$911.9M	$882.7M
Liabilities, Current	$465.2M	$520.2M	$497.7M	$471.3M	$438.3M
Long-term Debt	—	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$401.4M	$21.0M	$101.7M	$82.8M	$72.1M
Net Cash Provided by (Used in) Investing Activities	$53.4M	-$64.5M	-$66.2M	-$11.5M	-$141.8M
Net Cash Provided by (Used in) Financing Activities	-$289.7M	-$1.6M	$29.1M	-$2.2M	$6.8M
Payments to Acquire Property, Plant, and Equipment	$48.0M	$38.3M	$28.0M	$42.2M	$90.9M
Payments for Repurchase of Common Stock	$200.3M	$200.3M	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)